USFDA May 2026 ANDA Approvals & Landmark Supreme Court IP Ruling USFDA May 2026 ANDA Approvals & Landmark Supreme Court IP Ruling
Summary of the blog post - 2 minutes read US Generic Pharma Update 2026: May ANDA Approvals & Landmark Supreme Court IP Ruling The U.S. generic pharmaceutical sector experienced a highly active period in mid-2026, marked by a surge in regulatory clearances and a historic legal decision from the nation's highest court . In this comprehensive regulatory roundup, we break down the USFDA’s May 2026 Abbreviated New Drug Application (ANDA) approvals, highlight key product launches from top Indian manufacturers, and analyse a landmark Supreme Court patent decision that reshapes the legal landscape for generic drug entry . 1. USFDA May 2026 ANDA Approvals Analysis Overview The USFDA maintained a high pace of regulatory reviews in May 2026, issuing a total of 65 ANDA approvals , of which 20 were tentative . What is a Tentative Approval? A tentative approval indicates that a generic drug application has fully met all of the USFDA’s rigid scientific, quality, safety, and...